Structure of Maribavir
CAS No.: 176161-24-3
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Maribavir proves to be a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, displaying an IC50 of 3 nM. It exhibits potent antiviral activity against HCMV and Epstein-Barr virus (EBV).
Synonyms: GW257406X; 1263W94; VP-41263
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 176161-24-3 |
Formula : | C15H19Cl2N3O4 |
M.W : | 376.24 |
SMILES Code : | CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O |
Synonyms : |
GW257406X; 1263W94; VP-41263
|
MDL No. : | MFCD00945570 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Akata cells | 20 μM | 24 hours | MBV almost completely inhibited the appearance of the 54-kDa and 52-kDa EA-D products and also reduced the level of 49-kDa EA-D | PMC2786727 |
Akata cells | 20 μM | 24 hours | MBV inhibits phosphorylation of EBV early antigen EA-D | PMC2786727 |
293 cells | 20 μM | 48 hours | MBV inhibits EBV transcription and replication by inhibiting BGLF4 protein kinase activity | PMC3624302 |
Human foreskin fibroblasts (HFF) | 10 µM | 5 to 6 days | To evaluate the effect of MBV on GCV antiviral activity, results showed MBV increased GCV EC50 by 13-fold | PMC1610080 |
Human embryonic lung (HEL) fibroblasts | 0.32 µM | 5 to 6 days | To evaluate the effect of MBV on GCV antiviral activity, results showed MBV increased GCV EC50 by ninefold | PMC1610080 |
Human foreskin fibroblast (HFF) | 0.5-25 μM | 5-20 passages | Selection of UL97 and UL27 mutations, discovery of new UL97 mutation L337M and UL27 mutations D534Y, R448P | PMC3398170 |
ARPEp cells | 48.0 μM | 6 days | Evaluate the inhibitory effect of Maribavir on L397R mutant CMV, EC50 was 48.0 μM | PMC10922325 |
ARPEp cells | 0.118 μM | 6 days | Evaluate the inhibitory effect of Maribavir on wild-type CMV, EC50 was 0.118 μM | PMC10922325 |
MRC-5 fibroblasts | 40 μM | 72 hours | Evaluate the inhibitory effect of MBV on hCMV DNA synthesis, results showed MBV alone reduced viral DNA levels by an average of 95% | PMC3845884 |
U373 cells | 40 μM | 72 hours | Evaluate the inhibitory effect of MBV on hCMV DNA synthesis, results showed MBV alone reduced viral DNA levels by an average of 40% | PMC3845884 |
Human embryonic lung fibroblasts | 0.1-10 μM | weekly passage | To evaluate the antiviral activity of Maribavir against CMV and the emergence of resistance mutations | PMC2612169 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00002373 | Cytomegalovirus Infections|HIV... More >> Infections Less << | PHASE1 | COMPLETED | - | Univ of California/ San Franci... More >>sco / Dept of Medicine, San Francisco, California, 94110, United States|Dr Jacob Lalezari, San Francisco, California, 94115, United States Less << |
NCT00411645 | Cytomegalovirus Infections | Phase 3 | Completed | - | - |
NCT00497796 | Cytomegalovirus Infections | Phase 3 | Completed | - | - |
NCT00411645 | - | Completed | - | - | |
NCT02927067 | Cytomegalovirus (CMV) | Phase 3 | Recruiting | August 13, 2021 | - |
NCT00223925 | Cytomegalovirus Infection | Phase 2 | Completed | - | United States, California ... More >> City of Hope Medical Center Duarte, California, United States UCLA Medical Center Los Angeles, California, United States United States, Illinois Loyola University Maywood, Illinois, United States United States, Massachusetts Tufts-New England Medical Center Boston, Massachusetts, United States United States, Michigan Wayne State Medical Center Detroit, Michigan, United States United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States United States, North Carolina Duke Medical Center Durham, North Carolina, United States United States, Texas Baylor University Medical Center Dallas, Texas, United States MD Anderson Cancer Center Houston, Texas, United States United States, Utah University of Utah Salt Lake City, Utah, United States United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States Less << |
NCT00497796 | - | Completed | - | - | |
NCT02931539 | Cytomegalovirus (CMV) | Phase 3 | Recruiting | May 6, 2019 | - |
NCT01611974 | Cytomegalovirus (CMV) | PHASE2 | COMPLETED | 2014-12-05 | UCLA Medical Center, Los Angel... More >>es, California, 90095, United States|Stanford University Medical Center, Stanford, California, 94305, United States|University of Colorado, Denver, Colorado, 80045, United States|Yale University, New Haven, Connecticut, 06520, United States|University of Florida, Gainesville, Florida, 32610, United States|Tampa General Hospital, Tampa, Florida, 33614, United States|Emory University, Atlanta, Georgia, 30322, United States|Northwestern University Medical Center, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21205, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|University of Massachusetts, Worcester, Massachusetts, 01655, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Henry Ford Health Care System, Detroit, Michigan, 48202, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55454, United States|University of Nebraska, Omaha, Nebraska, 68198, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 30322, United States|Wake Forest Medical Center, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States|University of Pittsburg, Pittsburgh, Pennsylvania, 15213, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Vanderbilt Medical Center, Nashville, Tennessee, 37212, United States|Methodist Healthcare System, San Antonio, Texas, 78229, United States|University of Utah, Salt Lake City, Utah, 84132, United States|University of Washington, Seattle, Washington, 98109, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98195, United States Less << |
NCT02775240 | Cytomegalovirus (CMV) | Phase 1 | Completed | - | United States, Florida ... More >> Clinical Pharmacology of Miami, Inc. Miami, Florida, United States, 33014 Less << |
NCT01611974 | Cytomegalovirus (CMV) | PHASE2 | COMPLETED | 2014-12-05 | UCLA Medical Center, Los Angel... More >>es, California, 90095, United States|Stanford University Medical Center, Stanford, California, 94305, United States|University of Colorado, Denver, Colorado, 80045, United States|Yale University, New Haven, Connecticut, 06520, United States|University of Florida, Gainesville, Florida, 32610, United States|Tampa General Hospital, Tampa, Florida, 33614, United States|Emory University, Atlanta, Georgia, 30322, United States|Northwestern University Medical Center, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21205, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|University of Massachusetts, Worcester, Massachusetts, 01655, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Henry Ford Health Care System, Detroit, Michigan, 48202, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, 55454, United States|University of Nebraska, Omaha, Nebraska, 68198, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 30322, United States|Wake Forest Medical Center, Winston-Salem, North Carolina, 27157, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, 19141, United States|University of Pittsburg, Pittsburgh, Pennsylvania, 15213, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Vanderbilt Medical Center, Nashville, Tennessee, 37212, United States|Methodist Healthcare System, San Antonio, Texas, 78229, United States|University of Utah, Salt Lake City, Utah, 84132, United States|University of Washington, Seattle, Washington, 98109, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98195, United States Less << |
NCT05137717 | Cytomegalovirus (CMV) | PHASE3 | COMPLETED | 2023-06-27 | Ehime University Hospital, Too... More >>n, Ehime, Japan|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|Sapporo Hokuyu Hospital, Sapporo-Shi, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Sapporo City General Hospital, Sapporo, Hokkaido, Japan|University of Tsukuba Hospital, Tsukuba-shi, Ibaraki, Japan|Imamura General Hospital, Kagoshima-shi, Kagoshima, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Yochomachi Clinic, Shinjuku-ku, Tokyo, Japan|Chiba University Hospital, Chiba, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Kyoto University Hospital, Kyoto, Japan|Okayama University Hospital, Okayama, Japan|Osaka Metropolitan University Hospital, Osaka, Japan|Jichi Medical University Saitama Medical Center, Saitama, Japan Less << |
NCT05319353 | Cytomegalovirus (CMV) | PHASE3 | ACTIVE_NOT_RECRUITING | 2027-01-18 | University of Nebraska Medical... More >> Center -985400 Nebraska Medical Center, Omaha, Nebraska, 68114-4113, United States|Cincinnati Children's Hospital Medical Center - PIN, Cincinnati, Ohio, 45229-3026, United States|Cook Children's Health Care System, Fort Worth, Texas, 76104-2733, United States|University of Texas MD Anderson Cancer Center - 1515 Holcombe Blvd, Houston, Texas, 77030-4000, United States|Sydney Children's Hospital, Randwick, New South Wales, 2031, Australia|Queensland Children's Hospital, South Brisbane, Queensland, 4101, Australia|Royal Children's Hospital Melbourne - PIN, Parkville, Victoria, 3052, Australia|Perth Children's Hospital, Nedlands, Western Australia, 6009, Australia|H?pital Universitaire des Enfants Reine Fabiola (HUDERF), Bruxelles, Brussels, 1020, Belgium|Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Brussels, 1200, Belgium|UZ Gent, Gent, Oost-Vlaanderen, 9000, Belgium|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de S?o Paulo, Porto Alegre, Rio Grande Do Sul, 90160-093, Brazil|Hospital Do Rim E Hipertens?o, S?o Paulo, 04038-002, Brazil|Children's Hospital Capital Institute of Pediatrics, Beijing, Beijing, 100020, China|Beijing Children's Hospital, Capital Medical University - PIN, Beijing, Beijing, 100045, China|Shanghai Children's Medical Center, Shanghai, Shanghai, 200127, China|Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences - PPDS, Tianjin, Tianjin, 300020, China|CHU de Rennes - H?pital Pontchaillou, Rennes, Ille-et-Vilaine, 35200, France|CHU de Grenoble Alpes - H?pital Michallon, La Tronche, Isère, 38700, France|CHRU Nantes, Nantes, Loire-Atlantique, 44000, France|Hopital Necker, Paris, 75015, France|Universit?tsklinikum Würzburg, Würzburg, Bayern, 97080, Germany|Universit?tsklinikum Münster, Münster, Nordrhein-Westfalen, 48149, Germany|Universitatsklinikum Jena - Am Klinikum 1-Erlanger Allee 101, Jena, Thüringen, 07745, Germany|Universit?tsklinikum Hamburg Eppendorf, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|The Chaim Sheba Medical Center - PPDS, Ramat Gan, Tel-Aviv, 52394, Israel|Tel Aviv Sourasky Medical Center Ichilov - PPDS, Tel Aviv-Yafo, Tel-Aviv, 64239, Israel|Rambam Health Care Campus - PPDS, Haifa, 31096, Israel|Hadassah Medical Center- Ein Kerem - PPDS, Petah Tiqva, 4920235, Israel|National Center for Child Health and Development, Nagoya-Shi, Aiti, 453-0046, Japan|Saitama Children's Medical Center, Isehara-Shi, Kanagawa, 259-1143, Japan|Shizuoka Children's Hospital, Aoi-ku, Sizuoka, 420-8660, Japan|Hyogo Prefectural Kobe Children's Hospital, Chiba-Shi, 650-0047, Japan|Osaka Women's and Children's Hospital, Izumi-Shi, ?saka, 594-1101, Japan|Hospital Sant Joan de Deu - PIN, Espluges De Llobregat, Barcelona, 08950, Spain|Hospital Universitario La Paz - PPDS, Horcajo de la Sierra, Madrid, 28755, Spain|Hospital Regional Universitario de Malaga - Hospital Materno-Infantil, Malaga, Málaga, 29011, Spain|Hospital Universitario Vall d′Hebron- PPDS, Barcelona, 08035, Spain|Hospital Infantil Universitario Ni?o Jesus - PIN, Madrid, 28009, Spain|King's College Hospital, London, Lambeth, SE5 9RS, United Kingdom|Royal Manchester Children's Hospital - PIN, Manchester, Lancashire, M13 9WL, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Birmingham Women's and Children's NHS Foundation Trust, Birmingham, West Midlands, B4 6NH, United Kingdom|Great Ormond Street Hospital, London, WC1N 3JH, United Kingdom Less << |
NCT05382104 | Healthy Volunteers | PHASE1 | COMPLETED | 2022-07-02 | Celerion, Lincoln, Nebraska, 6... More >>8502, United States Less << |
NCT04131556 | Healthy Volunteers | PHASE1 | TERMINATED | 2020-01-06 | Clinical Pharmacology of Miami... More >>, Llc, Miami, Florida, 33014, United States Less << |
NCT06577363 | Cytomegalovirus (CMV) | RECRUITING | 2031-08-30 | Takeda selected site, Tokyo, J... More >>apan Less << | |
NCT06439342 | Cytomegalovirus (CMV) | PHASE3 | NOT_YET_RECRUITING | 2027-02-05 | Peking University People's Hos... More >>pital, Beijing, North China, 100044, China Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.66mL 0.53mL 0.27mL |
13.29mL 2.66mL 1.33mL |
26.58mL 5.32mL 2.66mL |
Tags: Maribavir | 1263W94 | BW1263W94 | GW257406X | EBV | CMV | Epstein-Barr Virus | Cytomegalovirus | CMV inhibitor | pUL97 kinase inhibitor | antiviral therapy | cytomegalovirus treatment | immunocompromised patient | 176161-24-3
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL